According to Fortune Business Insights, the global HBsAg testing market was valued at USD 1.44 billion in 2025 and is projected to grow from USD 1.53 billion in 2026 to USD 2.44 billion by 2034, registering a CAGR of 6.07% during the forecast period. North America dominated the market with a 38.89% share in 2025. The market is expanding due to the increasing prevalence of hepatitis B, growing awareness regarding early diagnosis, government-led screening initiatives, and continuous advancements in diagnostic technologies.
Growing Burden of Hepatitis B Supporting Market Expansion
The increasing burden of hepatitis B is the primary factor driving the HBsAg testing market. HBsAg tests are widely used to diagnose hepatitis B virus (HBV) infection by detecting the hepatitis B surface antigen. According to the World Health Organization (WHO), nearly 254 million people were living with hepatitis B globally in 2022, highlighting the growing need for effective screening and diagnosis. Rising disease prevalence has encouraged healthcare providers to increase routine screening, particularly among high-risk populations, including pregnant women, blood donors, and healthcare workers. These developments continue to generate strong demand for HBsAg diagnostic products worldwide.
Government Screening Programs Accelerating Market Growth
Fortune Business Insights identifies government initiatives and regulatory guidelines as another major growth driver. Healthcare authorities across several countries are strengthening hepatitis B screening programs to reduce disease transmission and improve early diagnosis. For instance, the U.S. Centers for Disease Control and Prevention (CDC) recommends HBsAg testing for all pregnant women during the first trimester, infants born to HBsAg-positive mothers, and adults aged 18 years and above at least once in their lifetime. Such public health recommendations are increasing testing volumes globally and supporting market expansion.
Get a Free Sample PDF - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/hbsag-testing-market-110984
Technological Advancements Strengthening Diagnostic Capabilities
Continuous product innovation is improving the accuracy, sensitivity, and efficiency of HBsAg testing. Manufacturers are focusing on advanced immunoassay technologies that deliver faster and more reliable results while supporting laboratory automation. The growing adoption of chemiluminescence immunoassay (CLIA), enzyme-linked immunosorbent assay (ELISA), and chromatographic immunoassays is enhancing diagnostic performance across hospitals and clinical laboratories. In addition, companies are investing in rapid diagnostic tests and point-of-care solutions to improve accessibility, particularly in underserved healthcare settings.
Segment Analysis
By Type
The qualitative segment dominates the global HBsAg testing market and accounted for 93.6% of the market share in 2026. Its leadership is attributed to the increasing burden of hepatitis B and the growing focus of manufacturers on launching technologically advanced qualitative testing products. Meanwhile, the quantitative segment is expected to witness substantial growth due to the rising prevalence of chronic hepatitis B and the increasing number of diagnostic laboratories performing quantitative testing.
By Technique
The chemiluminescence immunoassay (CLIA) segment held the largest market share of 48.28% in 2026. Fortune Business Insights attributes this dominance to the expanding application of CLIA-based platforms for hepatitis B antigen testing and their superior analytical sensitivity. The ELISA segment remains the second-largest contributor because of its cost-effectiveness and proven diagnostic reliability, while chromatographic immunoassays continue to support rapid testing applications.
By Setting
The laboratory-based segment is projected to dominate the market with a 97.24% share in 2026. Its leadership is driven by the increasing number of clinical laboratories conducting HBsAg tests and the availability of advanced diagnostic infrastructure. At the same time, the point-of-care segment is expected to grow at the fastest rate due to rising adoption of rapid testing solutions capable of delivering quick diagnostic results in decentralized healthcare settings.
By Sample Type
The blood segment is expected to account for 91.62% of the global market in 2026, making it the leading sample type. Fortune Business Insights attributes this dominance to government initiatives promoting hepatitis B screening through blood tests and the high diagnostic accuracy associated with blood-based testing. Plasma remains the second-largest segment, supported by increasing regulatory approvals and expanding product availability.
By End User
Clinical laboratories represent the leading end-user segment owing to the growing number of HBsAg tests being conducted in these facilities. Expanding laboratory networks, improved diagnostic infrastructure, and rising hepatitis B screening volumes continue to strengthen this segment's market position. Hospitals and clinics are also expected to record significant growth as routine patient screening and preventive healthcare initiatives continue to expand globally.
Regional Analysis
North America generated USD 0.56 billion in revenue in 2025, accounting for 38.89% of the global market. The region benefits from strong healthcare infrastructure, high diagnostic testing rates, and substantial government funding for hepatitis B prevention. Europe held the second-largest regional share, supported by increasing healthcare expenditure and expanding hepatitis B awareness initiatives. Asia Pacific is projected to register the fastest CAGR throughout the forecast period due to the high prevalence of hepatitis B in countries such as China and India, growing healthcare investments, and expanding public awareness campaigns.
Competitive Landscape
Fortune Business Insights identifies Siemens Healthineers AG, F. Hoffmann-La Roche Ltd., and Abbott as the leading companies operating in the HBsAg testing market. These companies are focusing on product innovation, regulatory approvals, strategic partnerships, and expansion of their diagnostic portfolios to strengthen their competitive position. Recent FDA approvals and investments in advanced immunoassay technologies are expected to enhance diagnostic capabilities and improve global access to hepatitis B testing solutions throughout the forecast period.